SCHEMBL21709220

SCHEMBL21709220

c1ccc(-c2ccccc2N(c2nc(-c3ccccc3)c3ccccc3n2)c2cccc3c2C2(c4ccccc4-c4ccccc42)c2ccccc2-3)cc1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 3/20 0.46
MAPT P10636 4/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
GAA P10253 2/20 0.37
ADORA2A P29274 3/20 0.37
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 3/20 0.36
HPGD P15428 3/20 0.36
GLA P06280 1/20 0.36
NPSR1 Q6W5P4 1/20 0.34
SCN9A Q15858 2/20 0.34
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
RAD52 P43351 1/20 0.33
LMNA P02545 3/20 0.32
HTT P42858 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709283 0.89 NUDT1 (0.44) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709222 0.89 NUDT1 (0.44) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709379 0.84 MEN1 (0.45) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709372 0.83 NUDT1 (0.43) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709223 0.82 NUDT1 (0.41) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709506 0.80 NUDT1 (0.40) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL24078283 0.79 THRB (0.35) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL16544725 0.79 THRB (0.35) MAPTMEN1KMT2AALDH1A1KDM4E
SCHEMBL21709462 0.79 NUDT1 (0.44) NUDT1MAPTMEN1KMT2AGAA
SCHEMBL21709503 0.79 MEN1 (0.47) NUDT1MAPTMEN1KMT2AGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT NUDT1 15/4885MAPT 4008/4885MEN1 2014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.